Diadem Secures US Patent for Blood-Based Alzheimer’s Disease Biomarker Detection
The patent expands intellectual property coverage for the blood-based assay ahead of its planned commercial launch.
Category: Dementias & Alzheimer’s
Dementias & Alzheimer’s
Latest
Dementias & Alzheimer’s
Latest
Ultrasonic Blood Test Method Shows High Accuracy for Alzheimer’s Detection
Researchers at Xuanwu Hospital have developed an ultrasonic blood test method that detects Alzheimer’s with over 90% accuracy by measuring plasma amyloid-beta seeding activity.
Dementias & Alzheimer’s
Latest
UK Researchers Evaluate Alzheimer’s Blood Test in Primary Care
Imperial College London has begun integrating C2N’s PrecivityAD2 blood test into primary care pathways for Alzheimer’s diagnosis, as part of the BEAD-PC study and the Davos Alzheimer’s Collaborative initiative.
Roche to Share New Data on Elecsys Alzheimer’s Blood Tests at AAIC
Presentations will evaluate the performance of the company’s pTau217 and pTau181 assays while also highlighting phase 3 clinical research for the investigational therapy trontinemab for Alzheimer’s disease.
Read More
Beckman Coulter Receives CE Mark for Automated p-Tau217 Alzheimer’s Blood Test
The p-Tau217 assay runs on the DxI 9000 Immunoassay Analyzer, enabling laboratories to incorporate blood-based Alzheimer’s biomarker testing into high-throughput workflows.
Read More
First Commercial Alzheimer’s Tau Tangle Blood Test Launches
The eMTBR-Tau assay measures tau tangle pathology in blood, with potential applications in Alzheimer’s disease staging, clinical trials, and therapy monitoring.
Read More
Lilly to Present Data Comparing P-Tau217 Blood Tests With Amyloid PET at AAIC
Presentations at the upcoming Alzheimer’s Association International Conference include data comparing P-tau217 blood biomarker tests with amyloid PET, along with new long-term safety findings for donanemab.
Read More
Spear Bio to Release New Alzheimer’s Disease Tests and Automated Instrument Platform
The company is introducing blood-based assays for tau biomarkers and a platform to automate laboratory workflows.
Read More
Blood Circular RNAs Outperform pTau217 in Predicting Alzheimer’s Disease Progression
A new NIH-funded study finds that elevated circular RNAs in blood may predict Alzheimer’s symptoms years in advance, outperforming current blood tests in forecasting disease progression.
Read More
Study Supports Prognostic Value of Alzheimer’s Biomarkers in Adults Over 80 With Mild Cognitive Impairment
Research indicates that blood and cerebrospinal fluid tests provide relevant prognostic information for elderly patients, challenging the idea that aging makes these tests less useful.
Read More
Mount Sinai Researchers Identify Blood RNA Biomarkers for Alzheimer’s Detection
The study highlights the role of brain-derived nanoparticles in identifying the disease through minimally invasive testing.
Read More
ALZpath and Abbott Partner to Develop New Blood Test for Alzheimer’s Disease
The agreement will integrate a specific antibody into diagnostic tests for use on widely installed immunoassay systems.
Read More
Sysmex Europe Launches Automated Blood Testing Platform for Alzheimer’s Disease
The system uses routine blood draws to provide results in 17 minutes, offering an alternative to invasive diagnostic methods.
Read More
A Year of Firsts for Alzheimer’s Blood Testing
With the first FDA-cleared test and clinical guidelines debuting since May 2025, labs are evaluating how blood-based biomarkers fit into diagnostic protocols.
Read More
Can an Alzheimer’s Blood Test Detect Early, Subtle Cognitive Decline?
Biomarkers in midlife adults without dementia may be linked to the earliest signs of waning cognition, researchers found.
Read More
Could a Blood Test Predict Risk of Brain Swelling During Alzheimer’s Treatment?
Researchers have identified a blood-based biomarker panel that may identify Alzheimer’s disease patients at increased risk for brain swelling or bleeding associated with new anti-amyloid therapies.
Read More
Researchers Develop Blood Test Sensor for Early Alzheimer’s and Parkinson’s Detection
The sensor identifies misfolded protein biomarkers in blood before clinical symptoms of neurodegeneration appear.
Read More
FDA Grants Breakthrough Designation to Urine-Based Alzheimer’s Test
The test uses urinary volatile organic compound patterns and machine learning to aid in the diagnosis of Alzheimer’s disease.
Read More